 "-mul-", for example, is never reduced to "-mu-" because no chimeric or humanized antibodies targeting the musculoskeletal system ever received an INN.Combination of target and source substems results in endings like "-limumab" (immune system, human) or "-ciximab" (circulatory system, chimeric, consonant "r" dropped).New and shorter target substems were adopted in 2009.